A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 349 participants.
Also called NCT06184568
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 349 participants
- Registry
-
NCT06184568
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06184568. Randomized; no masking; primary purpose treatment. Start 2024-02-29 (actual); primary completion 2025-09-17 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
- Condition
- Type 2 Diabetes
- Condition
- Obesity
- Intervention (Drug)
- IBI362
- Intervention (Drug)
- Semaglutide
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Record details
- Record id
cardio:ct-nct06184568- Content hash
889459636c07018dc9856d356614452977069f0494a28bb095ab101da39f52a2